FIELD: biotechnologies.
SUBSTANCE: invention describes polynucleotide, expression vector, host cell and production method of humanised antibody together with their use, as well as medical preparation against rheumatoid arthritis, prophylaxis or treatment method of rheumatoid arthritis and use of humanised antibody at production of pharmaceutical preparation for prophylaxis or treatment of rheumatoid arthritis. This invention can be used in therapy of human diseases associated with α9 integrin.
EFFECT: improved activity and thermal stability.
14 cl, 6 dwg, 6 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-OSTEOPANTINE RECOMBINANT ANTIBODY AND USES THEREOF | 2002 |
|
RU2305111C2 |
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
| CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS | 2003 |
|
RU2346701C2 |
| CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
| HUMANISED ANTIBODIES TO CDCP1 | 2010 |
|
RU2571207C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| PEPTIDE OR PEPTIDE COMPLEX BINDING TO alpha2- INTEGRIN, METHODS FOR PRODUCTION AND USE THEREOF | 2011 |
|
RU2588668C2 |
